Reports of safety issues with some of these products, such as recombinant erythropoietins, have raised concerns about the quality of these biologics.45-48 For example, increased rates of pure red-cell aplasia were observed in patients with chronic kidney disease who received subcutaneous administration of recombinant human erythropoietin compared with the reference product. This evidence concerns the gene EPO and Pure red cell aplasia.